20Slash20 Inc., the innovator behind The Eye Drink—the world’s first clinically inspired, ready-to-drink functional beverage formulated to minimize ocular issues in today’s screen-heavy world—has been featured in coverage of the upcoming Disruptive Growth & Life Sciences Conference hosted by Moody Capital Solutions Inc. The conference, set to showcase disruptive companies in growth and life sciences sectors, will provide a platform for 20Slash20 to present its novel approach to preventive eyecare.
The Eye Drink is specifically designed for individuals who spend long hours daily staring at computer or cellphone screens, aiming to mitigate screen-induced dry eyes and macular damage. Leveraging science-backed nutrients based on AREDS 2 Studies and vegan-friendly triglyceride-formed Omega-3, the beverage seeks to protect visual performance and improve ocular comfort. By incorporating these clinically studied ingredients into a convenient drink, 20Slash20 is transforming clinical science into a simple, delicious, and enjoyable daily habit.
The company operates through direct-to-consumer channels, professional medical affiliates, and natural product retail stores, modernizing the way preventive eyecare is delivered. As digital device usage continues to rise globally, the potential impact of such products is significant. Eye strain and related conditions have become widespread public health concerns, affecting productivity and quality of life. The introduction of a functional beverage that addresses these issues could offer a practical solution for millions of screen-dependent workers and consumers.
Industry experts note that the convergence of nutrition and technology in health products is a growing trend, and The Eye Drink represents a pioneering entry into the ocular health beverage niche. With the global market for functional beverages expanding, products that target specific health concerns—such as eye strain—are well-positioned to capture consumer interest. Furthermore, the company’s use of AREDS 2-based nutrients, which have been studied for age-related macular degeneration, adds credibility and could appeal to both younger screen users and older adults concerned about long-term vision health.
The conference, organized by Moody Capital Solutions, an independent full-service investment bank with over 40 years of experience in capital raising, M&A, and advisory services, is recognized as a market leader in rights offerings. For more information about the conference or to register to attend, visit https://moodycapital.com/conference/. IBN, a multifaceted financial news and publishing company, is providing comprehensive coverage of the event, including summaries of participating companies and syndicated articles to maximize visibility. To view IBN’s coverage of the conference, visit https://ibn.fm/MoodyCapital2026Conference.
The inclusion of 20Slash20 in this conference underscores the investment community’s growing interest in innovative health solutions that address modern lifestyle challenges. As the company continues to expand its distribution and awareness, its participation in such events could pave the way for strategic partnerships and funding opportunities, potentially accelerating the availability of The Eye Drink to a broader audience. For more information on 20Slash20 and The Eye Drink, visit the company’s website at theeyedrink.com.
